Stephen A. Tullman - Net Worth and Insider Trading
Stephen A. Tullman Net Worth
The estimated net worth of Stephen A. Tullman is at least $674,336 dollars as of 2024-10-02. Stephen A. Tullman is the Director of Aclaris Therapeutics Inc and owns about 571,471 shares of Aclaris Therapeutics Inc (ACRS) stock worth over $674,336. Details can be seen in Stephen A. Tullman's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Stephen A. Tullman has not made any transactions after 2018-10-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Stephen A. Tullman
Stephen A. Tullman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Stephen A. Tullman owns 1 companies in total, including Aclaris Therapeutics Inc (ACRS) .
Click here to see the complete history of Stephen A. Tullman’s form 4 insider trades.
Insider Ownership Summary of Stephen A. Tullman
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ACRS | Aclaris Therapeutics Inc | 2018-10-04 | director |
Stephen A. Tullman Latest Holdings Summary
Stephen A. Tullman currently owns a total of 1 stock. Stephen A. Tullman owns 571,471 shares of Aclaris Therapeutics Inc (ACRS) as of October 4, 2018, with a value of $674,336.
Latest Holdings of Stephen A. Tullman
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics Inc | 2018-10-04 | 571,471 | 1.18 | 674,336 |
Holding Weightings of Stephen A. Tullman
Stephen A. Tullman Form 4 Trading Tracker
According to the SEC Form 4 filings, Stephen A. Tullman has made a total of 0 transactions in Aclaris Therapeutics Inc (ACRS) over the past 5 years. The most-recent trade in Aclaris Therapeutics Inc is the acquisition of 7,100 shares on October 4, 2018, which cost Stephen A. Tullman around $99,400.
Insider Trading History of Stephen A. Tullman
- 1
Stephen A. Tullman Trading Performance
GuruFocus tracks the stock performance after each of Stephen A. Tullman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Stephen A. Tullman is -26.57%. GuruFocus also compares Stephen A. Tullman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Stephen A. Tullman within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Stephen A. Tullman's insider trading performs compared to the benchmark.
Performance of Stephen A. Tullman
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -0.05 | | | | | |
| Relative Return to S&P 500(%) | -0.48 | | | | | |
Stephen A. Tullman Ownership Network
Stephen A. Tullman Owned Company Details
What does Aclaris Therapeutics Inc do?
Who are the key executives at Aclaris Therapeutics Inc?
Stephen A. Tullman is the director of Aclaris Therapeutics Inc. Other key executives at Aclaris Therapeutics Inc include Chief Scientific Officer Joseph Monahan , Chief Financial Officer Kevin Balthaser , and Chief Business Officer James Loerop .
Aclaris Therapeutics Inc (ACRS) Insider Trades Summary
Over the past 18 months, Stephen A. Tullman made no insider transaction in Aclaris Therapeutics Inc (ACRS). Other recent insider transactions involving Aclaris Therapeutics Inc (ACRS) include a net purchase of 4,854,052 shares made by Braden Michael Leonard , a net sale of 18,000 shares made by Joseph Monahan , and a net purchase of 14,705 shares made by James Loerop .
In summary, during the past 3 months, insiders sold 0 shares of Aclaris Therapeutics Inc (ACRS) in total and bought 1,154,418 shares, with a net purchase of 1,154,418 shares. During the past 18 months, 18,000 shares of Aclaris Therapeutics Inc (ACRS) were sold and 4,878,247 shares were bought by its insiders, resulting in a net purchase of 4,860,247 shares.
Aclaris Therapeutics Inc (ACRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aclaris Therapeutics Inc Insider Transactions
Stephen A. Tullman Mailing Address
Above is the net worth, insider trading, and ownership report for Stephen A. Tullman. You might contact Stephen A. Tullman via mailing address: C/o Aclaris Therapeutics, Inc., 101 Lindenwood Drive, Suite 400, Malvern Pa 19355.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
